List of Excipients in Branded Drug INVANZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	INVANZ	ertapenem sodium	0006-3843	SODIUM BICARBONATE
Merck Sharp & Dohme LLC	INVANZ	ertapenem sodium	0006-3843	SODIUM HYDROXIDE

INVANZ Excipient Strategy and Commercial Opportunities: Ertapenem Injection Market Analysis

Last updated: August 9, 2026

Invanz is a once-daily carbapenem antibiotic containing ertapenem sodium for intravenous or intramuscular administration. Its commercial formulation is a sterile lyophilized powder that uses a minimal excipient system: sodium bicarbonate and sodium hydroxide for pH control, with sodium chloride infusion solution used for intravenous dilution and lidocaine hydrochloride used for intramuscular reconstitution.[1] The principal commercial opportunities are generic sterile manufacturing, ready-to-administer delivery, improved reconstitution, lower-cost packaging, global presentations, and hospital supply reliability.

The formulation is technically simple but commercially difficult to replicate at scale. The main barriers are sterile powder processing, carbapenem stability, container-closure integrity, reconstitution performance, particulate control, and regulatory comparability.

What is the Invanz formulation and which excipients does it contain?

Invanz contains ertapenem sodium equivalent to 1 gram of ertapenem per vial. The product is supplied as a sterile lyophilized powder for intravenous infusion or intramuscular injection.[1]

Formulation element	Role in Invanz
Ertapenem sodium	Active pharmaceutical ingredient
Sodium bicarbonate	pH adjustment and buffering
Sodium hydroxide	pH adjustment
Sterile water for injection	Reconstitution medium
0.9% sodium chloride injection	Intravenous dilution vehicle
1% lidocaine hydrochloride injection	Optional intramuscular reconstitution vehicle

The commercial product does not depend on a complex surfactant, preservative, lipid, polymer, or controlled-release system. This creates a low-excipient profile but places greater technical importance on the active ingredient, pH, freeze-drying cycle, residual moisture, and reconstitution conditions.

The FDA label directs intravenous reconstitution with 10 mL of sterile water for injection or 0.9% sodium chloride injection, followed by dilution into 50 mL of 0.9% sodium chloride. Intramuscular administration uses 1% lidocaine hydrochloride injection without epinephrine as the reconstitution solvent.[1]

How does the Invanz excipient strategy affect product development?

The excipient strategy is designed around chemical stability and clinical flexibility rather than patient-facing formulation differentiation.

pH control is the central excipient function

Ertapenem is a beta-lactam carbapenem and is vulnerable to degradation in aqueous environments. The vial therefore uses a dry-state presentation and limits the excipient system to pH-adjusting agents. Sodium bicarbonate provides buffering capacity, while sodium hydroxide permits final pH adjustment.

A generic developer should treat pH as a critical quality attribute. Small changes can affect:

• Ertapenem assay and degradation products
• Reconstituted solution stability
• Color and clarity
• Container compatibility
• Intramuscular tolerability
• Batch-to-batch release performance

Replacing sodium bicarbonate with another buffer could create a regulatory advantage only if it improves stability, reconstitution, or manufacturing robustness without changing the product’s pharmaceutical equivalence profile.

Lyophilization creates the main technical challenge

The vial format avoids long-term storage of an aqueous carbapenem solution. The product must retain cake structure, potency, sterility, and rapid reconstitution through the labeled shelf life.

The key development variables include:

Variable	Commercial relevance
Freezing rate	Affects cake structure and reconstitution
Primary drying temperature	Controls collapse and product stability
Secondary drying	Controls residual moisture
Residual moisture	Influences degradation and shelf life
Stoppering under vacuum or inert gas	Affects oxidation and container integrity
Vial fill accuracy	Directly affects dose uniformity
Reconstitution time	Influences hospital workflow

An improved lyophilized cake with faster dissolution could support a differentiated hospital product, but the benefit must be measurable. A modest reduction in preparation time is more likely to support formulary adoption when paired with a closed transfer device, premixed bag, or automated pharmacy workflow.

What excipient strategies could create commercial differentiation?

The strongest opportunities involve process and presentation improvements rather than novel excipients.

1. Optimized buffer system

A developer could evaluate different bicarbonate concentrations or alternative alkaline agents to improve:

• Dry-state stability
• Reconstitution speed
• Solution clarity
• Degradation control
• Compatibility with vial and stopper materials

The regulatory risk is higher when the buffer system changes materially from the reference formulation. The developer would need to establish pharmaceutical equivalence, stability, impurity control, and clinical suitability under the applicable abbreviated new drug application pathway.

2. Low-moisture lyophilized formulation

A lower residual-moisture product could improve shelf life and reduce sensitivity to temperature excursions. This is commercially relevant in markets with weak cold-chain infrastructure or long distribution routes.

The opportunity is strongest where a manufacturer can combine:

• Robust lyophilization
• High-barrier glass vials
• Improved stopper performance
• Better secondary packaging
• Validated room-temperature stability

Invanz itself is stored at controlled room temperature and does not require refrigerated storage before reconstitution.[1]

3. Faster-reconstituting powder

Hospital pharmacists value products that reduce preparation steps. A more porous cake, optimized fill volume, or improved vial geometry could reduce shaking and dissolution time.

A faster product could be marketed to:

• Emergency departments
• Operating rooms
• Intensive-care units
• Outpatient parenteral antimicrobial therapy programs
• Home infusion providers

The commercial advantage is greater for a ready-to-use or premixed presentation than for a small improvement in vial reconstitution.

4. Preservative-free single-dose packaging

A preservative-free, single-dose vial is consistent with injectable hospital use and reduces concerns about preservative exposure. Multi-dose packaging could lower packaging cost but would introduce sterility, antimicrobial-preservative, and in-use stability requirements. For ertapenem, a multi-dose presentation would likely provide limited clinical value relative to the added regulatory and microbiological burden.

5. Device-enabled administration

A manufacturer could pair generic ertapenem with:

• Closed-system transfer devices
• Dual-chamber containers
• Ready-to-use IV bags
• Prefilled syringes for selected settings
• Pharmacy bulk packages
• Elastomeric infusion systems

These approaches may support a separate device or combination-product strategy. They also create additional manufacturing and human-factors obligations.

What formulation patents protect Invanz and its generic opportunities?

The principal historic protection for Invanz centered on ertapenem and its pharmaceutical use. The original U.S. compound and product exclusivity periods have expired, allowing generic ertapenem injection products to enter the market. The FDA lists Invanz under NDA 021337 and identifies generic ertapenem injection products through its approved drug databases and Orange Book framework.[2]

Protection category	Invanz relevance	Current commercial effect
Ertapenem compound patents	Covered the active molecule and related carbapenem chemistry	Historic protection; expired
Product formulation patents	Could cover injectable composition or stability features	Must be checked against current Orange Book listings
Method-of-use patents	Could cover treatment of specified infections	Limited effect if expired or not listed
Pediatric exclusivity	Extended certain FDA exclusivity periods	Historic, not a current barrier
Manufacturing patents	Could cover synthesis, purification, or crystallization	May remain relevant outside the core product estate
Device patents	Could cover premixed or dual-chamber delivery	Potential current differentiation area

The commercial center of gravity has moved from molecule-level exclusivity to manufacturing execution, procurement contracts, supply reliability, and delivery format. A new generic entrant should perform a current Orange Book and global patent-family review before launch because manufacturing and device patents may not appear in the same way as listed drug patents.

When did Invanz lose exclusivity and what is the generic entry position?

Invanz was approved by the FDA in November 2001.[1] Its branded exclusivity period ended years ago, and generic ertapenem injection products are commercially available in the United States.

The relevant current market structure is:

Market segment	Status
Originator product	Invanz, Merck
Active ingredient	Ertapenem sodium
Dosage form	Sterile injectable lyophilized powder
Administration	Intravenous or intramuscular
Generic pathway	ANDA-based generic competition
Biosimilar pathway	Not applicable
Main competition	Generic injectable manufacturers and hospital-contract suppliers

Ertapenem is a small-molecule antibiotic, not a biologic. Biosimilar risk therefore does not apply. The relevant competitive threat is generic substitution and therapeutic substitution within the carbapenem class.

What FDA regulatory status and Orange Book issues affect ertapenem injection?

FDA approval requires the generic product to demonstrate pharmaceutical equivalence and bioequivalence or applicable equivalence under the abbreviated pathway. For an injectable product, the major regulatory issues include:

• Active ingredient identity and strength
• Sterility assurance
• Endotoxin control
• Particulate matter
• Reconstitution performance
• Stability and degradation products
• Container-closure integrity
• Extractables and leachables
• Labeling and administration compatibility
• Manufacturing-site compliance

Because ertapenem is administered parenterally, the product has a narrower tolerance for formulation and manufacturing variability than an oral solid dosage form.

Paragraph IV litigation risk is lower than during the original patent period because the core Invanz protection has expired. It can still arise if a manufacturer challenges a later-listed formulation, method-of-use, device, or manufacturing patent. A generic applicant may instead file a Paragraph III certification, a Section viii statement for non-patented uses, or a Paragraph IV certification depending on the current Orange Book record.[2,3]

What generic launch scenarios exist for Invanz?

Low-cost standard vial

The most direct strategy is a 1-gram single-dose vial closely matching the reference product. This approach minimizes clinical switching concerns and targets hospital group purchasing organizations, integrated delivery networks, and government tenders.

The disadvantages are price compression and limited product differentiation.

Ready-to-use IV presentation

A premixed 1-gram IV bag could reduce pharmacy preparation. The main technical issues are aqueous stability, storage period, bag compatibility, shipping temperature, and microbial control.

This format could command a higher price than a conventional vial if it reduces labor and medication-preparation risks. It may also be attractive to outpatient infusion providers.

Dual-chamber system

A dual-chamber container can separate ertapenem from the diluent until administration. It can extend dry-state stability while avoiding manual reconstitution.

The opportunity depends on device cost. A dual-chamber product is more likely to succeed in home infusion, emergency care, and decentralized hospital settings than in high-volume inpatient procurement where vial cost dominates.

Premium hospital workflow product

A manufacturer could combine ertapenem with a closed transfer device or simplified preparation kit. The product would compete on total cost of administration rather than acquisition price.

This strategy requires evidence that the package reduces preparation time, contamination risk, or medication errors.

Emerging-market room-temperature product

A formulation with improved thermal stability could support markets with unreliable refrigeration and long distribution chains. This opportunity is commercially relevant but requires local regulatory submissions, country-specific packaging, and supply-chain validation.

How does Invanz compare with competing carbapenems?

Invanz has a distinct commercial position because once-daily dosing supports outpatient and step-down parenteral therapy. Meropenem and imipenem-cilastatin are often used in more severe hospital infections and typically require more frequent dosing, while doripenem has had limited commercial relevance after safety and market issues.

Product	Active drug	Typical commercial distinction
Invanz	Ertapenem	Once-daily dosing; broad outpatient utility
Merrem or generic meropenem	Meropenem	Broad hospital use; frequent dosing
Primaxin or generic imipenem-cilastatin	Imipenem-cilastatin	Broad-spectrum inpatient therapy
Vabomere	Meropenem-vaborbactam	Beta-lactamase inhibitor combination
Recarbrio	Imipenem-cilastatin-relebactam	Carbapenem plus inhibitor combination

Ertapenem does not provide the same antipseudomonal positioning as meropenem or imipenem-cilastatin. Its value is concentrated in appropriate infections where once-daily dosing, lower administration burden, and outpatient suitability matter.[1,4]

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can participate in the ertapenem market through qualified pharmaceutical-grade materials rather than branded-product licensing.

Potential supply opportunities include:

• Low-endotoxin sodium bicarbonate
• Sodium hydroxide meeting injectable-grade specifications
• Sterile water systems
• High-performance elastomeric stoppers
• Type I glass vials
• Low-permeability secondary packaging
• Lyophilization-compatible vial systems
• Ready-to-use infusion bags
• Closed transfer and reconstitution devices

The most defensible supplier position is often created through regulatory documentation, global DMF support, consistent particle and endotoxin profiles, and validated compatibility with the customer’s lyophilization cycle.

A supplier with a proprietary excipient blend may obtain formulation or process protection, but the practical value depends on whether the blend materially improves stability, manufacturing yield, or shelf life. Commodity sodium bicarbonate and sodium hydroxide alone offer limited differentiation.

What manufacturing and intellectual-property barriers remain?

The primary barriers are operational rather than molecule-level patent barriers.

Sterile manufacturing

A manufacturer needs validated aseptic processing or terminal sterilization-compatible operations. Ertapenem’s sensitivity to heat and aqueous degradation makes sterile powder processing and aseptic filling central to the business case.

API control

Ertapenem sodium requires tight control of polymorphism, water content, degradation products, residual solvents, and microbiological quality. API supply disruptions can affect the entire finished-dose market.

Lyophilization capacity

Commercial lyophilization capacity is a major bottleneck. A manufacturer may have an approved formulation but lack sufficient vial throughput, cycle robustness, or global site redundancy.

Container-closure integrity

Carbapenem products require packaging that protects the dry powder and maintains sterility through distribution and handling. Stopper extractables and vial breakage can create regulatory and commercial problems.

Global patent coverage

Core U.S. compound protection has expired, but country-specific patent families, process patents, formulation claims, and device rights should be reviewed by jurisdiction. Europe, Japan, China, India, and emerging markets may have different historical expiry dates and enforcement records.

What litigation, settlement, and licensing issues affect Invanz?

Invanz does not present the active exclusivity profile associated with a currently patent-protected branded medicine. The central litigation risk has shifted to generic approval disputes, manufacturing patents, supply contracts, and device rights.

Public FDA materials identify the approved product and generic regulatory framework but do not establish a current commercial licensing premium for the Invanz brand.[1-3] Merck’s financial disclosures have not generally provided Invanz as a separately reported current revenue line, limiting direct measurement of brand-specific revenue exposure.[5]

For investors and manufacturers, the more relevant questions are:

• Whether the generic product has an FDA-approved manufacturing site
• Whether the supplier has sufficient sterile fill-finish capacity
• Whether the product is listed in hospital contracts
• Whether the applicant has a differentiated delivery system
• Whether the product can withstand generic price erosion
• Whether supply reliability supports premium purchasing

Key Takeaways

• Invanz is a lyophilized ertapenem sodium injection with a minimal excipient system.
• Sodium bicarbonate and sodium hydroxide provide the principal formulation functions.
• The strongest technical opportunities are improved lyophilization, reconstitution, thermal stability, packaging, and administration.
• Generic competition is established, and biosimilar risk does not apply.
• Standard single-dose vials face substantial price pressure.
• Ready-to-use bags, dual-chamber containers, and closed-transfer systems offer greater commercial differentiation.
• Sterile manufacturing, API quality, lyophilization capacity, and container-closure integrity are the main barriers.
• Current patent review should extend beyond the Orange Book to manufacturing, formulation, device, and country-specific patent families.
• The commercial value of a new excipient is highest when it improves measurable product performance or reduces hospital preparation cost.

FAQs

Is sodium bicarbonate essential to the Invanz formulation?

Sodium bicarbonate is part of the labeled Invanz formulation and contributes to pH control. A generic product may use a different excipient system only if it meets applicable pharmaceutical equivalence, stability, quality, and regulatory requirements.

Can ertapenem be formulated as a ready-to-use IV bag?

Potentially, but aqueous stability, degradation control, container compatibility, sterility, storage conditions, and shelf life must support the proposed presentation. A ready-to-use bag could reduce pharmacy labor but would have higher manufacturing and distribution costs than a lyophilized vial.

Does Invanz require a preservative?

The labeled single-dose vial does not rely on a preservative system. A multi-dose presentation would create additional sterility and in-use stability requirements.

Is there a commercial opportunity for intramuscular ertapenem?

Yes. Intramuscular administration supports outpatient care when intravenous access is undesirable or impractical. A product that simplifies lidocaine reconstitution or reduces preparation errors could target ambulatory and home-care settings.

What is the strongest patent strategy for a new ertapenem product?

The strongest opportunities are likely formulation, lyophilization-process, container-closure, device, and administration-system claims rather than expired compound claims. The commercial value depends on measurable improvements in stability, reconstitution, shelf life, or workflow.

References

1. U.S. Food and Drug Administration. (2023). Invanz (ertapenem for injection) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Patent certifications and exclusivity. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (2018). Antibacterial drugs for treatment of complicated intra-abdominal infections and complicated urinary tract infections: Regulatory and clinical considerations. FDA.

5. Merck & Co., Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Merck & Co., Inc.